Newsroom | 19944 results

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowin...

WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud, and AI-driven EHR, today announced that Texas-based Ferris Family Medicine, P.A./ Cardiometabolic Health Solutions is experiencing success as an early adopter of the eClinicalWorks AI Document Insights Assistant. The AI assistant generates quick summaries of various documents. For instance, practices often receive large faxes, sometimes 50 to 100 pages long. The AI assistant summarizes the fax into a few paragra...

SAN MATEO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, received IDE approval from the FDA, enabling the company to commence a global, pivotal, randomized controlled trial, the FULFILL Study, in the United States and Australia. ULF Neuromodulation will be delivered via leads implanted in the epidural space, also known as Spinal Cord Stimulation (SCS). Presidio is...

BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics appoints Aleksandra Faust as Chief Artificial Intelligence Officer...

OTTAWA, Ontario--(BUSINESS WIRE)--Multiview Financial Software, a leading provider of enterprise resource planning solutions (ERP) for healthcare, today announced it has been named a preferred technology partner of OCHIN. This alliance designates Multiview as an OCHIN preferred ERP provider, aiming to bolster the financial stability of community health centers and hospitals in OCHIN’s network and ensure high-quality healthcare access for all. OCHIN's mission centers on providing knowledge solut...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in generating real-world evidence (RWE) from high-quality healthcare data today announced a partnership with Kythera Labs, a leading healthcare data and technology company, adding to the growing number of datasets and use cases for the Atropos Evidence™ Network including oncology. This is the first step in a multiyear agreement between the two companies committed to turning data and knowledge of molecular biology in health and disease...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare’s proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagno...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus’ AI-powered data analytics platform, Lens, to analyze and...

BOSTON--(BUSINESS WIRE)--Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-respons...

SALT LAKE CITY--(BUSINESS WIRE)--HOYA Vision Care (https://www.hoyavision.com/) today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company’s 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The...